Copyright
©The Author(s) 2024.
World J Hepatol. Mar 27, 2024; 16(3): 331-343
Published online Mar 27, 2024. doi: 10.4254/wjh.v16.i3.331
Published online Mar 27, 2024. doi: 10.4254/wjh.v16.i3.331
Drug name (therapeutic class) | Drug sponsor | Phase |
Core/capsid inhibitors | ||
JNJ56136379 (JNJ-6379) | Janssen Pharmaceutics | II |
ABI-H0731 (Vebicorvir) | Assembly Biosciences | II |
Entry inhibitors | ||
Bulevirtide (Hepcludex, formerly Myrcludex) | Gilead Sciences | III |
Small interfering RNA | ||
GSK3228836 (Bepirovirsen) | Ionis Pharmaceuticals | III |
VIR-2218 | Vir Biotechnology | II |
VIR-3314 | Vir Biotechnology | II |
JNJ-73753989 (JNJ-3989, formerly ARO-HBV) | GlaxoSmithKline Pharmaceuticals | II |
Arbutus-729 (AB-729 or Imdusiran) | Arbutus Biopharma | II |
HBsAg inhibition | ||
REP 2139/REP 2165 | Replicor | II |
Toll-like receptor agonists | ||
GS-9620 (Vesatolimod) | Gilead Sciences | II |
GS-9688 (Selgantolimod) | Gilead Sciences | II |
Therapeutic vaccines | ||
GS-4774 | Gilead Sciences | II |
BRII-179 | Brii Biosciences | II |
Drug name (therapeutic class) | Drug sponsor | Phase | Trial ID | Study design | Study population | Sample size | Intervention and control | Primary outcome |
RG6346 (siRNA); RO7020531 (TLR-7 agonist) | Hoffman-La Roche | II | NCT04225715 | Randomized, open-label, parallel assignment | Chronic HBV infection patients on established NA monotherapy for ≥ 12 months, HBV DNA < 20 IU/mL, ALT ≤ 1.5 ULN | 280 | Control arm: NA; Experimental arms: (1) CpAM (RO7049389) + TLR-7 agonist (RO7020531) + NA; (2) siRNA (RG6346) + NA; (3) siRNA (RG6346) + PEG-IFN + NA; (4) siRNA (RG6346) + TLR (RO7020531) + NA; (5) siRNA (RG6346) + PD-L1 LNA (R07191863) + NA | Percentage of participants with HBsAg loss at 24 wk after end of treatment |
GC1102 (HBsAg neutralizing antibody) | Green Cross Corporation | II | NCT03801798 | Double-blind, randomized, placebo-controlled, parallel-group | Chronic HBV infection patients on NA ≥ 24 wk before screening | 42 | Control arm: NA + placebo; Experimental arm: NA + GC1102 | Proportion of participants with ≥ 1 log IU/mL reduction in HBsAg titer |
- Citation: Lam R, Lim JK. Advances in discovery of novel investigational agents for functional cure of chronic hepatitis B: A comprehensive review of phases II and III therapeutic agents. World J Hepatol 2024; 16(3): 331-343
- URL: https://www.wjgnet.com/1948-5182/full/v16/i3/331.htm
- DOI: https://dx.doi.org/10.4254/wjh.v16.i3.331